Veru saw the highest growth of 0.99% in patent filings in June and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Veru’s patent filings and grants. Buy the databook here.
Veru has been focused on protecting inventions in Australia(AU) with one publication in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 50% of filings. The Australia(AU), and United States(US) patent Office are among the top ten patent offices where Veru is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Veru
Patents related to Covid-19 and rare diseases lead Veru's portfolio
Veru has the highest number of patents in Covid-19 followed by, rare diseases. For Covid-19, nearly 67% of patents were filed and no patents were granted in Q2 2024.
Cardiovascular disease related patents lead Veru portfolio followed by inflammation, and asthma
Veru has highest number of patents in cardiovascular disease followed by inflammation, asthma, acute respiratory distress syndrome, and chronic obstructive pulmonary disease (copd).
For comprehensive analysis of Veru's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.